Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC
Press release – Oslo, Norway, February 20, 2023: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs (VA) BRAVO study at the ASCO Genitourinary Cancers Symposium (ASCO GU) which was held February 16-18, 2023 in San Francisco, USA. The clinical data demonstrated a significant decrease in the risk of recurrence & longer time to recurrence following Blue Light cystoscopy (BLC[®]) with Cysview[®] compared to White Light cystoscopy (WLC) alone.ASCO GU is a meeting of up to 5 000 healthcare professionals focused on genitourinary cancers,